JOP20190094A1 - مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) - Google Patents

مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)

Info

Publication number
JOP20190094A1
JOP20190094A1 JOP/2019/0094A JOP20190094A JOP20190094A1 JO P20190094 A1 JOP20190094 A1 JO P20190094A1 JO P20190094 A JOP20190094 A JO P20190094A JO P20190094 A1 JOP20190094 A1 JO P20190094A1
Authority
JO
Jordan
Prior art keywords
compounds
useful
triazolones
dhodh
trisubstituted
Prior art date
Application number
JOP/2019/0094A
Other languages
English (en)
Inventor
Nguyen Duy
Brian Sykes David
Nikolaus Gradl Stefan
Friedrich Nising Carl
Mueller Thomas
Stellfeld Timo
Christian Sven
El Sheikh Sherif
Kr?Ber Michael
Merz Claudia
Niehues Michael
Zhao Changjia
Gunther Judith
Liu Kery
SCH?FER Martina
Jie Zhou Han
James Ferrara Steven
Janzer Andreas
Zimmermann Katja
Eis Knut
Original Assignee
Broad Inst Inc
Massachusetts Gen Hospital
Harvard College
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc, Massachusetts Gen Hospital, Harvard College, Bayer Ag, Bayer Pharma AG filed Critical Broad Inst Inc
Publication of JOP20190094A1 publication Critical patent/JOP20190094A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

الملخص يتعلق الاختراع الحالي بتزويد مركبات تريازولون بالصيغة العامة (I): (I)، بحيث R1، R2، R3، R4، و R5 كما هي محددة هنا، وطريق لتحضير المركبات المذكورة، المركبات الوسيطة المفيدة لتحضير المركبات المذكورة، التراكيب الصيدلية وتوليفات تشتمل على المركبات المذكورة واستخدام المركبات المذكورة لتصنيع التراكيب الصيدلية لعلاج أو الوقاية من الامراض، بالتحديد اضطرابات فرط التكاثر، كعامل وحيد أو في توليفة مع مكونات فعالة أخرى.
JOP/2019/0094A 2016-10-27 2017-06-16 مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) JOP20190094A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/103643 2016-10-27
US201762569296P 2017-10-06 2017-10-06

Publications (1)

Publication Number Publication Date
JOP20190094A1 true JOP20190094A1 (ar) 2019-04-25

Family

ID=60164720

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0094A JOP20190094A1 (ar) 2016-10-27 2017-06-16 مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)

Country Status (26)

Country Link
US (4) US10815215B2 (ar)
EP (1) EP3532468B1 (ar)
JP (1) JP7084389B2 (ar)
KR (1) KR20190084954A (ar)
CN (2) CN115557907A (ar)
AU (1) AU2017351688B2 (ar)
BR (1) BR112019008458A2 (ar)
CA (1) CA3041643A1 (ar)
CL (1) CL2019001160A1 (ar)
CO (1) CO2019004137A2 (ar)
CR (1) CR20190212A (ar)
CU (1) CU24572B1 (ar)
DO (1) DOP2019000110A (ar)
EC (1) ECSP19030002A (ar)
GE (1) GEP20217248B (ar)
IL (1) IL266214B (ar)
JO (1) JOP20190094A1 (ar)
MX (1) MX2019005009A (ar)
NI (1) NI201900041A (ar)
PE (1) PE20191005A1 (ar)
PH (1) PH12019500932A1 (ar)
TN (1) TN2019000136A1 (ar)
TW (1) TW201827414A (ar)
UA (1) UA123688C2 (ar)
UY (1) UY37461A (ar)
WO (1) WO2018077923A1 (ar)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
CA3041650A1 (en) * 2016-10-27 2018-05-03 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
TW201945346A (zh) * 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法
EP3553052A1 (en) * 2018-04-10 2019-10-16 Bayer AG 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer
WO2019197269A1 (en) * 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
EP3858361A4 (en) 2018-09-28 2021-12-01 FUJIFILM Corporation ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR ACTIVATOR USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE
TW202043208A (zh) * 2019-01-11 2020-12-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
MX2021009521A (es) * 2019-02-07 2021-09-08 Janssen Biotech Inc Inhibidores de dihidroorotato deshidrogenasa.
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
EP3750892A1 (en) 2019-06-14 2020-12-16 Yerevan State University Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses
MX2022002470A (es) * 2019-08-29 2022-03-22 Janssen Biotech Inc Inhibidores de dihidroorotato deshidrogenasa sustituidos con urea.
CA3157223A1 (en) * 2019-10-10 2021-04-15 Janssen Biotech, Inc. Bi-aryl dihydroorotate dehydrogenase inhibitors
WO2021083182A1 (zh) * 2019-10-28 2021-05-06 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用
KR20220137709A (ko) * 2020-02-04 2022-10-12 얀센 바이오테크 인코포레이티드 다이하이드로오로테이트 탈수소효소 억제제로서의 헤테로사이클릭 화합물
EP3912627B1 (en) 2020-05-20 2022-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of coronavirus infections
WO2021240423A1 (en) * 2020-05-29 2021-12-02 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2021240424A1 (en) 2020-05-29 2021-12-02 Janssen Biotech, Inc. Indazole and benzoisoxazole dihydroorotate dehydrogenase inhibitors
WO2021238881A1 (zh) * 2020-05-29 2021-12-02 南京明德新药研发有限公司 三氮唑酮类化合物
WO2021240429A1 (en) 2020-05-29 2021-12-02 Janssen Biotech, Inc. Benzofuran and benzopyran dihydroorotate dehydrogenase inhibitors
KR20230039678A (ko) * 2020-07-14 2023-03-21 난징 젠샤인 파마슈티컬스 컴퍼니, 리미티드 Dhodh 억제제로서의 화합물
CN111773214B (zh) * 2020-07-17 2021-04-20 中国人民解放军军事科学院军事医学研究院 2,4,5-三取代的1,2,4-三唑酮在制备抗病毒药物中的用途
EP3960170A1 (en) 2020-08-25 2022-03-02 Bayer AG Dosing schedule for a method of treatment with dhodh inhibitors
GB2598624A (en) * 2020-09-07 2022-03-09 Lorico Aurelio Use of triazole analogues for inhibition of a tripartite VOR protein complex in multicellular organisms
WO2022063299A1 (zh) * 2020-09-28 2022-03-31 微境生物医药科技(上海)有限公司 用作dhodh抑制剂的1,2,4-三唑酮衍生物
WO2022070069A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2022070071A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2022167402A1 (en) 2021-02-02 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of therapy comprising administering a therapeutically effective combination comprising a dhodh inhibitor and an idh inhibitor
WO2023280181A1 (zh) * 2021-07-05 2023-01-12 微境生物医药科技(上海)有限公司 用作dhodh抑制剂的1,2,4-三唑酮衍生物及其制备方法和用途
WO2023093812A1 (zh) * 2021-11-26 2023-06-01 南京明德新药研发有限公司 三氮唑酮类化合物的晶型及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098896A (en) 1975-09-29 1978-07-04 Chevron Research Company 1-Halohydrocarbylthio-3-hydrocarbylthio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
DE3934081A1 (de) 1989-10-12 1991-04-18 Bayer Ag Sulfonylaminocarbonyltriazolinone
DE3709574A1 (de) 1987-03-24 1988-10-06 Bayer Ag Substituierte triazolinone
DE3936622A1 (de) 1989-11-03 1991-05-08 Bayer Ag Halogenierte sulfonylaminocarbonyltriazolinone
DE3936623A1 (de) 1989-11-03 1991-05-08 Bayer Ag Sulfonylaminocarbonyltriazolinone mit ueber schwefel gebundenen substituenten
DE4110795A1 (de) 1991-04-04 1992-10-08 Bayer Ag Sulfonylaminocarbonyltriazolinone mit ueber sauerstoff gebundenen substituenten
DE3916208A1 (de) 1989-05-18 1990-11-22 Bayer Ag Substituierte triazolone
DE4342190A1 (de) 1993-12-10 1995-06-14 Bayer Ag Verfahren und neue Zwischenprodukte zur Herstellung von Triazolinonen
DE4433968A1 (de) 1994-09-23 1996-03-28 Bayer Ag Verfahren zur Herstellung von Alkoxytriazolinonen
DE19627901A1 (de) 1996-07-11 1998-01-15 Bayer Ag Substituierte aromatische Carbonylverbindungen und ihre Derivate
US6444613B1 (en) 1999-03-12 2002-09-03 Hoechst Schering Agrevo Gmbh Defoliant
BRPI0922180A2 (pt) 2008-12-08 2015-12-29 Sirtris Pharmaceuticals Inc insoindolinona e análogos correlatos como moduladores de sirtuína
US20100184815A1 (en) 2008-12-19 2010-07-22 Luehr Gary W Agonists of peroxisome proliferator activated receptor-alpha
PT2611785E (pt) 2010-09-01 2014-09-09 Bayer Ip Gmbh Amidas de ácido n-(tetrazol-5-il)- e n-(triazol-5- il)arilcarboxílico e sua utilização como herbicidas
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN103006645A (zh) * 2011-09-27 2013-04-03 华东理工大学 2-氨基苯并噻唑衍生物作为dhodh抑制剂的应用
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
US20160251341A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted triazole compounds as serine protease inhibitors
CN106543139B (zh) 2015-09-17 2020-03-17 沈阳中化农药化工研发有限公司 一种三唑酮类化合物及其用途
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)

Also Published As

Publication number Publication date
KR20190084954A (ko) 2019-07-17
US11713304B2 (en) 2023-08-01
CO2019004137A2 (es) 2019-05-10
AU2017351688A1 (en) 2019-04-11
US10815215B2 (en) 2020-10-27
AU2017351688B2 (en) 2022-02-03
CN110023302B (zh) 2022-07-26
CN115557907A (zh) 2023-01-03
DOP2019000110A (es) 2019-05-31
EP3532468B1 (en) 2022-03-23
WO2018077923A1 (en) 2018-05-03
US20220135536A1 (en) 2022-05-05
EP3532468A1 (en) 2019-09-04
CU24572B1 (es) 2022-01-13
CL2019001160A1 (es) 2019-09-13
CA3041643A1 (en) 2018-05-03
PH12019500932A1 (en) 2020-01-20
JP7084389B2 (ja) 2022-06-14
UY37461A (es) 2018-05-31
IL266214B (en) 2021-10-31
US11130745B2 (en) 2021-09-28
CU20190045A7 (es) 2019-12-03
US20200377472A1 (en) 2020-12-03
CN110023302A (zh) 2019-07-16
UA123688C2 (uk) 2021-05-12
BR112019008458A2 (pt) 2019-07-09
TN2019000136A1 (en) 2020-10-05
MX2019005009A (es) 2019-08-12
US20210188805A9 (en) 2021-06-24
CR20190212A (es) 2019-06-24
PE20191005A1 (es) 2019-07-15
US20200123129A1 (en) 2020-04-23
GEP20217248B (en) 2021-04-26
TW201827414A (zh) 2018-08-01
US20230365524A1 (en) 2023-11-16
IL266214A (en) 2019-06-30
NI201900041A (es) 2019-06-11
JP2019533694A (ja) 2019-11-21
ECSP19030002A (es) 2019-05-31

Similar Documents

Publication Publication Date Title
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12018550173A1 (en) Pyrazolopyrimidine derivatives
PH12018502472A1 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
PH12020500257A1 (en) Quinoline derivatives for treating infections with helminths
PH12019501846A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
WO2018077944A3 (en) 4,5-annulated 1,2,4-triazolones
PH12019501034A1 (en) New anthelmintic quinoline-3-carboxamide derivatives
PH12019502851A1 (en) New azaquinoline derivatives
JO3447B1 (ar) 2-(مورفولين-4-يل)-7،1-نفثيريدينات
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
MX2019012803A (es) Nuevos derivados de pirazol biciclicos.
PH12020500134A1 (en) Dihydrooxadiazinones
WO2017198341A8 (en) MACROCYCLIC INDOLE DERIVATIVES
WO2020126968A3 (en) Urea derivatives for use against proliferative diseases
CR20220236A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
PH12020551891A1 (en) New quinoline derivatives
MX2020001323A (es) Metodos para tratar alteraciones del comportamiento.
PH12020550494A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
PH12016501932A1 (en) Amido-substituted azole compounds
PH12019500808A1 (en) Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof